Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

News & Analysis

China biotech company and industry news and analysis...

Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus

Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront

Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio

Bioheng Publishes Positive Results for Universal CAR-T in Hematological Malignancies

Week in Review: Sino Biopharm Subsidiary Enters $307 Million Agreement for Rights to NASH Candidate

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022